Editas Medicine (EDIT)
$16.67
1.48 (8.13%)
EDIT Stock Quote Delayed 30 Minutes
EDIT Stock: The Preclinical Data Sending Editas Medicine Rallying Today
After falling 60% year to date, EDIT stock is finally reversing course and trending higher in morning trading.
11 Best Stocks to Buy for 2022
He found Apple at $1.49... Oracle at $0.51... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 11 Stocks for 2022 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
1.14B
PE Ratio
-4.07
EPS
-4.1
Volume (Avg. Vol.)
1.01M
Day's Range
$16.67 - $18.10
52-Week Range
$18.11 - $73.03
Dividend & Yield
N/A (N/A)
EDIT Stock Predictions, Articles, and Editas Medicine News
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.
Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology.
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players.
Editas Stock Isn’t Worth Buying This Early Into Treatment Development
EDIT stock is part of a pioneering movement in CRISPR gene editing, but there's no way to know whether the company will succeed long term.
The Top 7 Gene-Editing Stocks to Buy for the Biggest Scientific Breakthrough of the Century
Doudna's breakthrough in CRISPR has since ushered in a new era of genetic engineering, making these the best gene-editing stocks to buy.
Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar
Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia.
Midday Market Update: 10 Biggest Stock Gainers Today
Good afternoon, investors! We're taking a look at how the market is doing halfway through the day with a midday market update.
What Will the Stock Market Do Today? 3 Big Stories to Watch.
So what will the stock market do today? All eyes are on gene-editing stocks like NTLA and on recovering crypto prices.
Gene Editing Stocks: The Big News Lifting EDIT, BNGO, CRSP and NTLA Stocks
Gene editing stocks are getting a boost on Monday morning after Intellia Therapeutics said it was successful using CRISPR gene-editing therapy directed inside the body to an internal organ.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning! Let's get ready for trading to start off strong this week with a look at the biggest pre-market stock movers for Monday!
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? Dogecoin prices and other cryptocurrencies stole the show, and CRISPR stocks sold off.
CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today
A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.
Goldman Sachs Just Put Editas Stock on Sale — Buy the Dip
Goldman says Editas' clinical data may underwhelm. We don't agree. So this is the time to buy the dip in EDIT stock.
Investing in CRISPR Stocks: Ultimate Genetic Editing Guide
The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.
Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT Are Doing Today
Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players.
A Play on the Biggest Scientific Breakthrough of the Century
There are only a handful of large, well-established gene editors with robust and mature therapy pipelines in the world today. Of those, one that stands out is a $4.8 billion biotechnology company by the name of Editas Medicine (NASDAQ:EDIT).
